Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Myeloid 1

Conditions

Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

fludarabine 33Specimen Handling 32Azacitidine 30venetoclax 29Cyclophosphamide 29Biopsy 25fludarabine phosphate 23Whole-Body Irradiation 19Cytarabine 19ruxolitinib 18Mycophenolic Acid 18Busulfan 18Tacrolimus 16asciminib 15Melphalan 14Injections 14Decitabine 14X-Rays 12Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12decitabine and cedazuridine drug combination 11Magnetic Resonance Spectroscopy 11Cyclosporine 11Sirolimus 10Peripheral Blood Stem Cell Transplantation 10Thiotepa 9Filgrastim 9nilotinib 7Methotrexate 7Imatinib Mesylate 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Emapalumab × Myeloid × 90 days × Clear all
NCT06996119 2026-05-11

Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
MyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡